Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Receives CAP Accreditation

NEW YORK (GenomeWeb) – Epic Sciences announced today that its San Diego laboratory has received accreditation from the College of American Pathologists.

Epic markets a platform it calls "no cell left behind," which isolates circulating tumor cells in an unbiased manner, allowing downstream analyses of single CTCs using genomic, proteomic, and morphologic approaches.

CAP accreditation is designed to ensure a high standard of care for the laboratory testing of patient samples. As part of the process, CAP inspectors examine a lab's records and quality control of procedures, as well staff qualifications, equipment, facilities, safety records, and overall management.

Epic Sciences said it has analyzed more than 10,000 blood samples from cancer patients and that its technology is being used in more than 58 active clinical trials.

The company received CLIA certification for its lab in early 2015.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.